Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Adverum Biotechnologies, Inc. | advm-10k_20191231.htm |
| EX-32.2 - EX-32.2 - Adverum Biotechnologies, Inc. | advm-ex322_443.htm |
| EX-32.1 - EX-32.1 - Adverum Biotechnologies, Inc. | advm-ex321_26.htm |
| EX-31.2 - EX-31.2 - Adverum Biotechnologies, Inc. | advm-ex312_18.htm |
| EX-31.1 - EX-31.1 - Adverum Biotechnologies, Inc. | advm-ex311_10.htm |
| EX-21.1 - EX-21.1 - Adverum Biotechnologies, Inc. | advm-ex211_24.htm |
| EX-10.36 - EX-10.36 - Adverum Biotechnologies, Inc. | advm-ex1036_1450.htm |
| EX-4.3 - EX-4.3 - Adverum Biotechnologies, Inc. | advm-ex43_598.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statements on Form S-8 Nos. 333-223894, 333-218465, 333-211439, 333-203398, 333-199296, 333-230138, 333-233135, and 333-220894 |
|
|
(2) |
Registration Statements on Form S-3 Nos. 333-219890 and 333-233134 |
of our reports dated March 12, 2020, with respect to the consolidated financial statements of Adverum Biotechnologies Inc. and the effectiveness of internal control over financial reporting of Adverum Biotechnologies, Inc. included in this Annual Report (Form 10-K) of Adverum Biotechnologies Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
San Jose, California
March 12, 2020